MedPath

Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes

Phase 4
Completed
Conditions
Azithromycin
Meconium Stained
Postpartum Endometritis
Interventions
Registration Number
NCT05118984
Lead Sponsor
Cairo University
Brief Summary

Meconium stained amniotic fluid increases the risk of maternal complications (e.g., dystocia, operative delivery, and postpartum endometritis) and neonatal complications (e.g., sepsis, admission to the neonatal intensive care unit \[NICU\], and meconium aspiration syndrome). The goal of the study is to compare between Azithromycin vs Placebo in cases of meconium stained amniotic fluid during the first stage of labor in multigravida women and their effect on maternal and neonatal outcomes.

Detailed Description

Meconium stained amniotic fluid, a troublesome situation both for obstetrician and pediatrician, it is associated with high rates of caesarean section, perinatal morbidity and mortality. The rate of meconium-stained amniotic fluid varies from 12 to 20%.It is higher in underdeveloped countries.Our study design would be a prospective randomized trial. Consented, eligible pregnant women presenting during the first stage of labor at or more than 37 weeks of gestation with meconium stained amniotic fluid will be randomized to receive Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12hrs on empty stomach for 3 days)(Group 1).Group 2 will be offered placebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule for 3 days).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
324
Inclusion Criteria
  1. Multigravida pregnant women with meconium stained amniotic fluid encountered either by spontaneous/artificial amniotomy during the first stage of labor in the ward provided that the gestational age at delivery is 37 weeks of gestation or more.
  2. Singleton living gestation
  3. Cephalic presentation
  4. Adequate pelvis
  5. An informed written consent for the proposed study.
Exclusion Criteria
  1. Primigravids
  2. Women with previous cesarean section
  3. Multifetal gestation
  4. Intrauterine fetal death
  5. Malpresentations
  6. Prematurity (<37 weeks )
  7. Abnormally invasive placenta during the current pregnancy
  8. Medical disorders with pregnancy
  9. Contracted pelvis
  10. Evidence of maternal infection
  11. Allergy to azithromycin or other macrolides that is self-reported or documented in the medical record.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Azithromycin groupAzithromycin capsule (Zithromax, Pfizer) (250 mg)Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).
Placebo groupPlaceboplacebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule every 12hrs for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2.
Primary Outcome Measures
NameTimeMethod
Azithromycin vs Placebo in cases of meconium stained amniotic fluid during the first stage of labor in multigravida women and their effect on occurrence of neonatal fever , pneumonia and skin infection .within 1 week from delivery

Neonates were followed up for incidence of neonatal pneumonia, neonatal skin infection , neonatal fever.

Azithromycin vs Placebo in cases of meconium stained amniotic fluid during the first stage of labor in multigravida women and their effect on occurrence of maternal fever, postpartum endometritis and skin (episiotomy/tear) infection.within 1 week from delivery

Mothers will be followed up during her stay in the postnatal ward regarding signs of infection (fever, maternal tachycardia, offensive vaginal discharge, uterine tenderness). Postpartum follow up visit 1 week after delivery will be conducted.

Secondary Outcome Measures
NameTimeMethod
2- Side effects of drug (diarrhea, stomach cramps, vomiting, allergy and anaphylactic shock).wwithin 1 week postpartum

Mothers follow up for incidence of side effects related to Azithromycin

Fetal necessity for NICU admission and/or mechanical ventilation.after delivery and within 1 week postartum

Incidence of NICU admission and/or mechanical ventilation in neonates born to women with MSAF

Occurrence of meconium aspirationafter delivery and within 1 week postpartum

Neonates will be followed up for presence or absence of meconium aspiration, APGAR score at 1 and 5 minutes, RDS.

Trial Locations

Locations (1)

Cairo University

🇪🇬

Giza, Egypt

© Copyright 2025. All Rights Reserved by MedPath